Swift, SeraCare partner on ctDNA standards, 4/16
April 2016—Swift Biosciences and SeraCare Life Sciences will partner to accelerate development of a novel circulating tumor DNA reference material.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Telepathology solution, 4/16
April 2016—Mikroscan Technologies released the SL5, a real-time telepathology and whole slide imaging solution for use in anatomic pathology applications.
Myriad expands collaboration with Tesaro and Merck, 4/16
April 2016—Myriad Genetics announced a strategic research collaboration with Tesaro and Merck (known as MSD outside the U.S. and Canada) to help identify potential responders to an investigational combination drug therapy using Tesaro’s PARP inhibitor (niraparib) plus Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.
Illumina acquires Conexio Genomics, 4/16
April 2016—Illumina has acquired Conexio Genomics, based in Fremantle, Western Australia.
Heating and cooling thermal mixer, 4/16
April 2016—Boekel Scientific introduced its Heat Cool Thermal Mixer II, which features a large intuitive touchscreen, interchangeable auto-recognized blocks to fit most laboratory consumables, multiple modes for increased process performance, and a large and accurate temperature and mixing range.
A1c-Cellular assayed for Ortho Vitros, 4/16
April 2016—Streck’s A1c-Cellular is now assayed for the Ortho-Clinical Diagnostics Vitros 4600. A1c-Cellular is an HbA1c control with intact red blood cells and tests the entire HbA1c procedure, including the lysing of the red blood cell.
Leica, Advanced Cell Diagnostics partnership, 4/16
April 2016—Leica Biosystems and Advanced Cell Diagnostics announced a comprehensive partnership to develop and commercialize tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridization assays on Leica’s Bond clinical advanced staining instruments.
FDA-cleared blood glucose monitoring system, 4/16
April 2016—LabStyle Innovations is preparing to launch its FDA-cleared Dario Blood Glucose Monitoring System in the United States.
Arquer, Euro Diagnostica agreement, 4/16
April 2016—Arquer Diagnostics has signed an agreement with Euro Diagnostica for the manufacturing and supply of Arquer’s Mcm5-ELISA test for the diagnosis of bladder cancer.
Flow cytometer, 4/16
April 2016—The BD FACSCelesta flow cytometer is designed to make multicolor flow cytometry more accessible and allow researchers to benefit from innovations in instrument and reagent technology.